Mel Max

Meloxicam, the active ingredient in Mel Max, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral tablet for oral use. It reduces pain and inflammation in osteoarthritis, rheumatoid arthritis and other musculoskeletal conditions.

GNH USA supplies Mel Max as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is used to manage inflammatory and painful conditions affecting the joints and musculoskeletal system.

- Osteoarthritis: alleviates joint pain and improves functional mobility. - Rheumatoid arthritis: decreases synovial inflammation and slows disease progression. - Musculoskeletal pain: provides analgesic relief for acute or chronic soft‑tissue discomfort.

Meloxicam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset (nausea, dyspepsia) - Headache - Dizziness - Peripheral edema - Skin rash - Elevated liver enzymes

Serious or Rare Side Effects: - Gastrointestinal ulcer or bleeding - Cardiovascular events (myocardial infarction, stroke) - Severe skin reactions (Stevens‑Johnson syndrome) - Hepatotoxicity - Renal impairment or failure - Anaphylaxis

Before prescribing meloxicam, clinicians should consider several safety precautions.

- Assess renal function: adjust use in patients with impaired kidneys. - Monitor hepatic function: avoid in severe liver disease. - Evaluate gastrointestinal risk: use cautiously in patients with ulcer disease or a history of bleeding. - Consider cardiovascular status: increased risk of thrombotic events in at‑risk individuals. - Review hypersensitivity: contraindicated in patients with known NSAID allergy. - Store at room temperature: keep in the original container, protect from moisture and light.

Meloxicam can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: heightened gastrointestinal toxicity. - Lithium: elevated lithium serum levels. - Methotrexate: reduced clearance, potential toxicity. - ACE inhibitors or ARBs: possible reduction in renal function.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal perfusion. - Antihypertensives: possible attenuation of blood‑pressure control. - SSRIs or SNRIs: additive bleeding risk. - Corticosteroids: increased gastrointestinal ulcer risk. - Cyclosporine: enhanced nephrotoxicity.